

pNiFty3-A-SEAP

AP-1-inducible reporter plasmid selectable with Zeocin™

Catalog code: pnf3-sp3

For research use only

Version 20L03-MM

PRODUCT INFORMATION

Content:

- 20 µg of pNiFty3-A-SEAP provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and stability:

- Products are shipped at room temperature.
- Store lyophilized DNA at -20 °C.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.

GENERAL PRODUCT USE

Pattern recognition receptor (PRR) activation triggers a complex signaling cascade that leads to the activation of different transcription factors, each playing an important role in the subsequent immune response. To monitor the induction of PRR signaling in response to ligand stimulation in a simple and efficient manner, InvivoGen has designed pNiFty, a family of reporter plasmids expressing a reporter gene under the control of a minimal promoter inducible by these different transcription factors, either individually or in combination. Most pNiFty plasmids are selectable with Zeocin™ in both *E. coli* and mammalian cells, and can be used to generate stable clones. pNiFty plasmids are composed of three key elements: a proximal promoter, repeated transcription factor binding sites (TFBS) and a reporter gene. The proximal promoters are shorter than 500 bp and contain transcription factor binding sites. Upon stimulation in 293 cells, their expression level remains undetectable. With the addition of repeated TFBS, the proximal promoters become inducible by the appropriate stimulus and drive the expression of the reporter gene.

PLASMID FEATURES

- **AP-1 binding site:** Activator protein 1 (AP-1) is a transcription factor activated by most PRRs. AP-1 is a heterodimeric complex composed of members of Fos, Jun and, ATF protein families. AP-1 binds to the TPA responsive element (TRE: ; TGAG/CTCA)¹. AP-1 activation in TLR signaling is mostly mediated by MAP kinases such as c-Jun N-terminal kinase (JNK), p38 and extracellular signal regulated kinase (ERK).
- **IFN-β promoter:** the mouse IFN-β minimal promoter comprises several positive regulatory domains that bind different cooperating transcription factors such as NF-κB, IRF3 and IRF7².
- **SEAP** is a secreted form of human embryonic alkaline phosphatase. Unlike endogenous alkaline phosphatases, SEAP is extremely heat stable and resistant to the inhibitor L-homoarginine. It catalyses the hydrolysis of pNitrophenyl phosphate (pNpp) producing a yellow end product. SEAP expression can be readily quantified by collecting samples of culture medium and measuring the hydrolysis of pNpp with a spectrophotometer at 405 nm.
- **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA.

- **Ori** is a minimal *E. coli* origin of replication with the same activity as the longer Ori.

• **EF1/HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter³ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat⁴. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

• **Zeo:** Resistance to the antibiotic Zeocin™ is conferred by the *Sh ble* gene from *Streptallocteichus hindustanus*. The *Sh ble* gene is driven by the EF1-HTLV promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁵.

1. Hess J, et al., 2004. AP-1 subunits: quarrel and harmony among siblings. *J Cell Sci.* 117(Pt 25):5965-73. **2.** Vodjani G, et al., 1988. Structure and characterization of a murine chromosomal fragment containing the interferon beta gene. *J Mol Biol.* 204(2):221-31. **3.** Kim D, et al., 1990. Use of the human elongation factor 1α promoter as a versatile and efficient expression system. *Gene* 91(2): 217-23. **4.** Takebe Y, et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell Biol.* 1: 466-72. **5.** Yu J & Russell J., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong : +852 3-622-34-80

E-mail: info@invivogen.com



NotI (-1)
1 **GCGGCCGCA**ATAAAATATCTTATTTCATTACATCTGTGTGGTTTTGTGAATCGTAACATACTACGCTCTCCATCAAACAAAAGAAC
PvuI (172)
101 AAACAAACTAGCAAAATAGGCTGCCAGTGCAAGTCAGGTGCCAGAACATTCTATCGAAGGATCTGCATCGCAGACT**TGAGTC**ACTGACTCA

Sdai (232)
EcoRI (225)

201 **GTGAGTC**ACTGACTCAG**TGAGTA**AGGAATTCT**CCTGCAG**GagttgaataaaatgaatattagaagctttagaataagagaaaatgacagaggaAAACT

301 **GAAAGG**gAGAACTGAAAGTggaaattcctctgaggcagaaaggaccatcc**TATAAA**tagcacaggccatgaaggaagatcattctactgcagcc

HindIII (422)

399 tttgacagccttcctcatcttg**AAGCTT**CTGCCTCTCCCTGTGAGTTGtaagtcaactgactgtctatgcctggaaaagggtggcaggagat

NsiI (544)
AvrII (537) XbaI (549)

499 **ggggcagtgc**aggaaaagtggcaactatgaaccc**TGAGCCTCTAGGAATGCATCTAGA**caattgtactaaccctttctcttccctcgtacag**GTTGG**
BsrGI (598) XcmI (611) SphI (632) Bsu36I (660)

599 **TGTACAGTAGCTCCACCATGATTCTGGGGCCTGCATGCTGCTGCTGCTGCTGCTGCTGCTGAGGCTACAGCTCTCCCTGGCATCATCCCAGTG
1▶ M I L G P C M L L L L L L L L L Q L Q L S L G I I P V**

699 AGGAGGAGAACCGGACTTCTGGAACCGCAGGGCAGCCGAGGCCCTGGTGGCCAAAGAAGCTGCAGCCTGCACAGACAGCCCAAGAACCTCATCAT
28▶ E E N P D F W N R E A A E A L G A A K K L Q P A Q T A A K N L I I
PvuII (833) **BamHI (842)**

799 CTTCTGGCGATGGATGGGATCTACGGTACAGTGCCAGGACTTAAAGGGCAGAAGAAGGACAACACTGGGCCCTGAGATACCCCTGGTATG
61▶ F L G D G M G V S T V T A A R I L K G Q K K D K L G P E I P L A M
NdeI (908)

899 GACCGCTTCCATATGTCGCTCTGCAAGACATACAATGTAGACAAACATGTAGCAGTGCCAGACAGTGGAGCCACAGCCACGGCTACCTGTGCGGGGTCAAGG
95▶ D R F P Y V A L S K T Y N V D K H V P D S G A T A T A Y L C G V K
999 GCAACTCCAGACCATGGCTTGAGTCAGCGCCCGCTTAAACAGTCACAGACAGCGGCAACGAGGTCTCGTGTATGAATCGGGCAAGAA
128▶ G N F Q T I G L S A A A R F N Q C N T T R G N E V I S V M N R A K K
BstEII (1119)

1099 AGCAGGGAAGTCAGTGGAGTGTAAACCACACAGACTGCCACACTGGACCCCTCCGTGGAGATGACAGAGGCTGCCCTGCGCTGAGCAGGAACCCCGC
161▶ A G K S V G V T R V Q H A S P A G T Y A H T V N R N W Y S D
1199 GCGACGTGCTGCCCTGGCCCGAGGAGGGTGCAGGACATCGCTACCGAGCTCATCCAAACATGGACATTGATGTGATCCCTGGTGGAGGCGAA
195▶ A D V P A S A R Q E G C Q D I A T Q L I S N M D I D V I L G G G R
1299 AGTACATGTTCGCATGGAACCCAGACCCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCGAGCTGGACGGGAAGAATCTGGTGCAGGAATGGCT
228▶ K Y M F R M G T P D P E Y P D D Y S Q G G T R L D G K N L V Q E W L
1399 GCGAAGCGCAGGGTGGCCGGTATGTGGAACCGCACTGAGCTATGAGGCTTCCCTGGACCCGCTGTGACCCATCTCATGGTCTCTTGAGCCT
261▶ A K R Q G A R Y V W N R T E L M Q A S L D P S V T H L M G L F E P
SacII (1593)

1499 GGAGACATGAAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCGTGGAGATGACAGAGGCTGCCCTGCGCTGAGCAGGAACCCCGC
295▶ G D M K Y E I H R D S T L D P S L M E M T E A A L R L L S R N P R
PshAI (1630)

1599 GCTTCTCCCTCTCGTGGAGGGTGTGCACTGACACCGTCATCACGAAAGCAGGGCTTACCGGGACTGACTGAGACGATCATGTTGACGACGCCAT
328▶ G F F L F V E G G R I D H G H H E S R A Y R A L T E T I M F D D A I
1699 TGAGAGGGCGGGCCAGCTACCAAGCGAGGGACACGCTGAGCTGCTACGCCACACTCCACGTCTCTCCCGAGGCTACCCCTGGAGGG
361▶ E R A G Q L T S E E D T L S L V T A D H S H V F S F G G Y P L R G
XcmI (1802) **StuI (1841)**

1799 AGCTCCATCTCGGGCTGGCCCTGGCAAGGCCGGACAGGAAGGCTACACGGCTCTCTATACGAAACGGTCAGGCTATGTGCTCAAGGACGGC
395▶ S S I F G L A P G K A R D R K A Y T V L L Y G N G P G Y V L K D G
BsrBI (1923)

1899 CCCGGCGGATTTACCGAGAGCGAGGGAGGCCGAGTATCGCAGCAGTCAGCTGGCCCTGGACGAAGAGACCCACGCAGCGAGGACGTGGC
428▶ A R P D V T E S E S G S P E Y R Q Q S A V P L D E E T H A G E D V A
BssHII (2005)

1999 GGTGTTCGCGCGCCCGCAGGGCGACCTGGTACGGCGTGCAGGAGCAGACCTTCAAGCGCACGTATGCCCTGCCCTGGAGGCC
461▶ V F A R G P Q A H L V H G V Q E Q T F I A H V M A F A A C L E P Y
NheI (2180)

2099 ACCGCTGCGACCTGGCGCCCCCGCAGGGCGACCCACCGACGCCGCACCCGGGGCGTCCGGTCAAGCGTCGGATTGAAGCTAGCTGGCAGACATG
495▶ T A C D L A P P A G T T D A A H P G R S R S K R L D •
2199 ATAAGATACATTGAGTTGGACAAACCAACTAGATCGAGTAAAAATGCTTATTGTGATGCTATTGCTTATTGTAACCA

HpaI (2318)

2299 TTATAAGCTGCAATAACAAGTTAACACAATTGATTCTATTTATGTTCAGGTTCAAGGGGAGGTGGAGGTTAAAGCAAGTAAACCT

EcoRI (2414)

2399 CTACAAATGTGGAT**TGGAATTCTAA**ATACGATAGCAAACCTTAAACCTCAAATCAAGCCTCTACTGAAATCTTTCTGAGGGATGAATAAGGCAT

2499 AGGCATCAGGGCTTGTCCAATGTGATTAGCTGTTGAGCCTCACCTCTTCAAGGTTAAAGATATAGTGTATTCTCAAGGTTGAAC

Swal (2667)

2599 TCTTCATTCTTATGTTAAATGCACTGACCTCCACATTCCCTTTAGTAAATATTCAAGAAATAATTAAATACATCATTGCAATGAAATAAAT

2699 GTTTTTATTAGGCAGAACATCCAGATGCTCAAGGCCCTCATATAATCCCCAGTTAGTAGTGGACTTAGGAAACAAGGAACCTTAATAGAAATTGG
2799 ACAGCAAGAACGAGCTTCAAGCTTCTAGCTTACCTCTGCTCTGCCACAAAGTCAGCAGCTGGCCGGGGCGCAGGGCAACTCCGCC
127▶ • G • D Q E E A V F H V C N G A P D R L A F E R G
2899 CACGGCTGCTCGCGATCTCGGTACGGCCGGCCGGAGGGCTCCGGAGTTCTGGACACGACCTCCGACACTCGCGTACAGCTCGCCAGGCC
101▶ W P Q E G I E T M A P G S A D R F N T S V V E S W E A Y L E D L G R
SgrAI (3082)

2999 GCACCCACACCCAGGCCAGGGTGTGTCGGCACCCACCTGGCTGGACCGCGCTGTGAAACAGGGTCACGTGCTCCGGACACCCGGCAAGTCGTC
68▶ V W V V W A L T N D P V V Q D Q V A S I F L T V D D R V V G A F D D
BsrBI (3145) BssHII (3161)

3099 CTCCACGAAGTCCGGAGAACCCGAGGCCGTCAGACTGACCGCTCCGGCGAGCAGCCGGAGCAGGGCACTGGTCAACTTG

35▶ E V F D R S F G L R D T W F E V A G A V D R A T L V P V A S T L K

NcoI (3199)
 3199 GCCATGGTGGCCCTCTATAGTGAGTCGTATTATACTATGCCGATATACTATGCCGATGATTAATGTCAACTACTGTTGTAGGCGCCGGTCACAGCTT
 1 A M
 3299 GGATCTGTAACGGCGCAGAACAGAAAACGAAACAAAGACGTAGAGTTGAGCAAGCAGGGTCAGGCAAAGCGTGGAGAGCCGGCTGAGTCTAGGTAGGCTC
 3399 CAAGGGAGGCCGGACAAAGGCCGGTCTGACCTGAGCTTAACCTACCTAGACGGCGACCCAGTTCAAGGAGGCACACAGGCCGGAGGCCAGAA

AseI (3257)
 3499 Bsu36I (3524)
 3499 CGCGACTCAACC CGCGTGGATGGCGGCCTCAGGTAGGGCGGGCGCGTGAAGGAGAGATGCAGGCCCCCTCGAAGCTTCAGCTGTGTTCTGGCGCAA

PvuII (3577)
 3599 HindIII (3571)
 3599 CCCGTTGCGAAAAAGAACGTTACGGCGACTACTGCACTTATACGGTTCTCCCCACCCCTGGGAAAAGGCCAGTACACGACATCACTTTCC

AgeI (3727)
 3699 SpeI (3796)
 3699 CAGTTACCCGCCACCTCTAGGCACCGGTTCAATTGCCGACCCCTCCCCCAACTCTCGGGACTGTGGCGATGTGCGCTCTGCCACTGAC

 SdaI (3806) PacI (3814)
 3799 TAGTGGGCCCTGCAGGTTAATT**ApaLI (4138)**
 3799 AGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGTTGCTGGCTTTCCATAGGCTC
 3899 CGCCCCCTGACGAGCATCACAAAGTGACGCTCAAGTCAGAGGTGGCGAACCCGACAGGACTATAAGATACCAGCGTTCCCTGGAGCTCCC
 3999 TCGTGCGCTCTCTGTTCCGACCCCTGCCGTTACCGGATACCTGTCGCCCTTCTCCCTGGGAAGCGTGGCGTTCTCATAGCTACGCTGTAGGTA

PacI (4554) SwaI (4563)
 4099 TCTCAGTTGGTGTAGGTGTTCGCTCCAAGCTGGCTGTGACGAACCCCCGTTCAGCCGACCGCTGCCCTATCGTAACATCGTCTTGAG
 4199 TCCAACCCGTAAGACACGACTTATGCCACTGGCAGCAGCCACTGTAACAGGATTAGCAGAGCGAGGTATGAGCCGTTACAGAGTTCTGAAGT
 4299 GGTGGCTAACTACGGCTACACTAGAAGAACAGTATTGGTATCGCCTCTGTAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTTGATCCG
 4399 CAAACAAACCACCGCTGGTAGCGGTGGTTTTGTTGCAAGCAGCAGATTACCGCAGAAAAAAAGGATCTCAAGAAGATCTTGATTTCTACG

 4499 GGGCTGACGCTAGGAAACAACTCACGTTAAGGGATTTGGCATGGCTAGTTAATTACATTTAAATCA